Mirum Pharmaceuticals, INC 8-K filings

Mirum Pharmaceuticals, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Mirum Pharmaceuticals announced the pricing of its $600 million offering of 0.00% Convertible Senior Notes due 2032, with net proceeds expected to be approximately $583.8 million.

Mirum Pharmaceuticals reported robust Q1 2026 results with increased net product sales and raised full-year guidance, alongside significant pipeline progress including a new drug application acceptance for zilurgisertib.

Mirum Pharmaceuticals announced its investigational drug volixibat met the primary endpoint in a Phase 2b study for primary sclerosing cholangitis (PSC), showing significant improvement in pruritus.

Mirum Pharmaceuticals announced positive primary endpoint results from the Phase 2b AZURE-1 study of brelovitug for chronic hepatitis delta virus.

Mirum Pharmaceuticals has amended its Form 8-K to include financial statements and pro forma information following its acquisition of Bluejay Therapeutics and a concurrent private placement.

Mirum Pharmaceuticals announced robust 2025 financial results, exceeding $521 million in net product sales, and provided an optimistic 2026 guidance with multiple key pipeline readouts anticipated.

Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding brelovitug for chronic hepatitis delta virus to its rare disease pipeline and securing $268.5 million in private placement financing.

Mirum Pharmaceuticals announced preliminary unaudited 2025 net product sales exceeding guidance, provided strong 2026 outlook, and detailed pipeline advancements including a proposed acquisition.

Mirum Pharmaceuticals has filed patent infringement lawsuits against multiple generic drug manufacturers seeking to market generic versions of its drug Livmarli, triggering a 30-month FDA approval stay.

Mirum Pharmaceuticals announced an additional $68.5 million private placement with TCGX to fund its proposed acquisition of Bluejay Therapeutics and related clinical development.

Mirum Pharmaceuticals announced the acquisition of Bluejay Therapeutics for $620 million upfront plus milestones, significantly expanding its rare liver disease portfolio with late-stage asset brelovitug and securing $200 million in private placement funding.

Mirum Pharmaceuticals received a Paragraph IV notice from Sandoz for generic Livmarli, prompting plans for patent infringement litigation.

Mirum Pharmaceuticals announced robust third-quarter 2025 financial results, including significant revenue growth and an updated full-year revenue guidance, alongside pipeline advancements.

Mirum Pharmaceuticals reported strong second quarter 2025 financial results, with total revenue of $127.8 million, and raised its full-year 2025 revenue guidance to $490 million to $510 million.

Mirum Pharmaceuticals, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where directors were elected, the independent auditor was ratified, and executive compensation was approved on an advisory basis.

Mirum Pharmaceuticals announces positive Q1 2025 financial results, highlighted by $111.6 million in revenue and increased full-year revenue guidance to $435-$450 million.

Mirum Pharmaceuticals announces positive 2024 financial results with $336.4 million in net product sales and provides a business update, including 2025 revenue guidance of $420 million to $435 million.

Mirum Pharmaceuticals announced preliminary unaudited 2024 net product sales of approximately $336 million, exceeding the upper end of its guidance, and provided a 2025 sales outlook of $420 to $435 million.

Mirum Pharmaceuticals announced a robust third quarter with significant sales growth, increased full-year guidance, and advancements in its clinical pipeline.

Mirum Pharmaceuticals announced a 139% increase in global net product sales for Q2 2024, reaching $77.8 million, and provided updates on its clinical pipeline and regulatory milestones.

Mirum Pharmaceuticals reported positive interim results from a Phase 2b trial of volixibat for primary biliary cholangitis (PBC), showing significant improvement in pruritus, and announced that a separate trial for primary sclerosing cholangitis (PSC) will continue.

Mirum Pharmaceuticals held its 2024 Annual Meeting of Stockholders, electing three Class II directors, ratifying Ernst & Young LLP as its auditor, and approving executive compensation on an advisory basis.

Mirum Pharmaceuticals announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for LIVMARLI for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients three months of age and older.

Mirum Pharmaceuticals announced a 137% increase in global product sales for Q1 2024 compared to Q1 2023, driven by strong demand for LIVMARLI and progress in regulatory milestones.

Mirum Pharmaceuticals announced a 142% increase in total revenue for 2023, reaching $186.4 million, driven by strong sales of LIVMARLI and the integration of CHOLBAM and CHENODAL.

Mirum Pharmaceuticals has promoted its Chief Operating Officer, Peter Radovich, to the additional role of President, effective January 16, 2024.